



UNIVERSITY OF LEEDS

This is a repository copy of *What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.*

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/114729/>

Version: Accepted Version

---

**Article:**

Moldovan, PC, Van den Broeck, T, Sylvester, R et al. (21 more authors) (2017) What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. *European Urology*, 72 (2). pp. 250-266. ISSN 0302-2838

<https://doi.org/10.1016/j.eururo.2017.02.026>

---

© 2017 European Association of Urology. Published by Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license  
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



									Moderate or high risk <b>Moderate risk:</b> GS 7 (GP4 >5%) and <50% of positive cores <b>or</b> GS 6-7 (GP4 ≤5%) and either ≥30% of positive cores or max core length invasion ≥8mm; <b>High risk:</b> GS ≥7 (GP4 >5%); ≥50% +cores <b>or</b> GS ≥8								
<b>Thompson 2014</b>	61.3%	Patient	35	16	76	23	68.6%	76.7%									
<b>Pokorny 2014</b>	63.7%	Patient	≥3/5: 56 ≥4/5: 74	≥3/5: 25 ≥4/5: 40	≥3/5: 101 ≥4/5: 86	≥3/5: 41 ≥4/5: 23	≥3/5: 69.1% ≥4/5: 64.9%	≥3/5: 71.1% ≥4/5: 78.9%	NR	NR	NR	NR	NR	NR	NR	NR	NR
<b>Petrillo 2014</b>	18.4%	Patient	56	4	21	55	93%	28%	NR	NR	NR	NR	NR	NR	NR	NR	NR
<b>Javali 2014</b>	16.4%	Patient	49	1	22	68	98%	24.4%	NR	NR	NR	NR	NR	NR	NR	NR	NR
<b>Abd-Alazeez 2014</b>	54.7%	Lobe	≥3/5: 33	≥3/5: 14	≥3/5: 127	≥3/5: 84	≥3/5: 70%	≥3/5: 60%	Def 1: GS ≥ 4+3	Def 1: 46	Def 1: 1	Def 1: 45	Def 1: 166	Def 1: 98	Def 1: 21		
									<b>and/or</b> maxCCL ≥ 6 mm	Def 2: 42	Def 2: 5	Def 2: 72	Def 2: 139	Def 2: 89	Def 2: 34		
									Def 2: GS ≥ 3+4	Def 3: 47	Def 3: 0	Def 3: 13	Def 3: 198	Def 3: 100	Def 3: 6		
									<b>and/or</b> maxCCL ≥ 4 mm	Def 4: 43	Def 4: 4	Def 4: 50	Def 4: 161	Def 4: 92	Def 4: 24		
									Def 3: 23.2%	Def 5: 46	Def 5: 1	Def 5: 39	Def 5: 172	Def 5: 98	Def 5: 19		
									Def 4: 36%	Def 6: 43	Def 6: 4	Def 6: 59	Def 6: 152	Def 6: 91	Def 6: 28		
									Def 4: GS ≥4+3	Def 1: 140	Def 1: 9	Def 1: 37	Def 1: 72	Def 1: 94	Def 1: 34		
<b>Abd-Alazeez 2014</b>	47,2%	Lobe	≥4/5: 87	≥3/5: 62	≥3/5: 79	≥3/5: 30	≥3/5: 58%	≥3/5: 73%	Def 2: 44.2%	Def 2: 42	Def 2: 5	Def 2: 72	Def 2: 139	Def 2: 89	Def 2: 34		
									<b>and/or</b> maxCCL ≥ 4 mm	Def 3: 23.2%	Def 4: 43	Def 4: 4	Def 4: 50	Def 4: 161	Def 4: 92	Def 4: 24	
									Def 3: 23.2%	Def 5: 46	Def 5: 1	Def 5: 39	Def 5: 172	Def 5: 98	Def 5: 19		
									Def 4: 36%	Def 6: 43	Def 6: 4	Def 6: 59	Def 6: 152	Def 6: 91	Def 6: 28		
									Def 4: GS ≥4+3	Def 1: 140	Def 1: 9	Def 1: 37	Def 1: 72	Def 1: 94	Def 1: 34		
									Def 4: GS ≥3+4	Def 5: 32.9%	Def 5: 1	Def 5: 39	Def 5: 172	Def 5: 98	Def 5: 19		
									Def 4: GS ≥3+4	Def 6: 39.5%	Def 6: 4	Def 6: 59	Def 6: 152	Def 6: 91	Def 6: 28		
<b>Abd-Alazeez 2014</b>	47,2%	Lobe	≥4/5: 49	≥4/5: 25	≥4/5: 26	≥4/5: 8	≥4/5: 66%	≥4/5: 76%	Def 5: maxCCL ≥ 6mm	Def 3: 18,5%	Def 3: 39	Def 3: 0	Def 3: 5	Def 3: 64	Def 3: 100	Def 3: 7	
									Def 6: maxCCL ≥ 4mm	Def 4: 21,3%	Def 4: 36	Def 4: 3	Def 4: 20	Def 4: 49	Def 4: 92	Def 4: 29	
									Def 5: maxCCL ≥ 6mm	Def 5: 16,7%	Def 5: 37	Def 5: 2	Def 5: 16	Def 5: 53	Def 5: 95	Def 5: 23	
									Def 6: maxCCL ≥ 4mm	Def 6: 25%	Def 6: 32	Def 6: 7	Def 6: 20	Def 6: 49	Def 6: 82	Def 6: 29	
									Def 5: maxCCL ≥ 6mm	Def 1: 70	Def 1: 4	Def 1: 16	Def 1: 18;	Def 1: 94	Def 1: 47		
									Def 6: maxCCL ≥ 4mm	Def 2: 63	Def 2: 11	Def 2: 23	Def 2: 11	Def 2: 85	Def 2: 67		
									Def 5: maxCCL ≥ 6mm	Def 3: 73	Def 3: 1	Def 3: 4	Def 3: 30	Def 3: 99	Def 3: 12		
<b>Matsuoka 2014</b>	64.8%	Lobe	46	49	149	26	48.4%	85.1%	Def 4: 68	Def 4: 68	Def 4: 6	Def 4: 17	Def 4: 17	Def 4: 92	Def 4: 50		
									Def 5: 70	Def 5: 70	Def 5: 4	Def 5: 14	Def 5: 20	Def 5: 94	Def 5: 41		
									Def 6: 64	Def 6: 64	Def 6: 10	Def 6: 17	Def 6: 17	Def 6: 86	Def 6: 49		

								≥10/15:								
<b>Junker 2013</b>	53.4%	Patient	≥10/15: 21 ≥11/15: 28	≥10/15: 4 ≥11/15: 12	≥10/15: 35 ≥11/15: 27	≥10/15: 13 ≥11/15: 6	≥10/15: 84% ≥11/15: 70%	72.9% ≥11/15: 81.8%	GS ≥4 + 3	13.7%	≥13: 54	≥13: 2	≥13: 8	≥13: 9	≥13: 96.4%	≥13: 47%
<b>Busetto 2013</b>	41.7%	Patient	59	7	61	36	89%	63%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Rais-Bahrami 2013</b>	54.2%	Patient	≥2/4: 80 ≥3/4: 251	≥2/4: 275 ≥3/4: 76	≥2/4: 187 ≥3/4: 16	≥2/4: 275 ≥3/4: 76	≥2/4: 66% ≥3/4: 51%	≥2/4: 59% ≥3/4: 82%	GS ≥7: GS ≥8	31.7%	NR	NR	NR	NR	GS ≥7: 91% GS ≥8: 91%	GS ≥7: 38% GS ≥8: 18%
<b>Kuru 2013</b>	57.6%	Patient	80	14	67	186	85.1%	73.5%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Ferda 2013</b>	51.2%	Patient	52	2	82	28	96.3%	74.5%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Ganie 2013</b>	74.7%	Patient	13	3	62	9	59.1%	95.4%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Vinet 2013</b>	49.3%	Patient	≥3/5: 11 ≥4/5: 22	≥3/5: 6 ≥4/5: 11	≥3/5: 28 ≥4/5: 23	≥3/5: 24 ≥4/5: 13	≥3/5: 64.7% ≥4/5: 66.7%	≥3/5: 53.8% ≥4/5: 63.8%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Numao 2013</b>	45%	Patient	137	57	101	56	70.6%	64.3%	Def 1: GS ≥4+3 and/or ≥20% positive cores and/or max CCL ≥5mm Def 2: GS ≥3+4and/or ≥20% +cores and/or maxCCL ≥5mm Def 3: GS ≥3+4 and/or ≥20% +cores	Def 1: 33.3% Def 2 :37.8% Def 3: 35.8%	Def 1: 74 Def 2: 65 Def 3: 69	Def 1: 83 Def 2: 92 Def 3: 88	Def 1: 160 Def 2: 153 Def 3: 156	Def 1: 34 Def 2: 41 Def 3: 38	Def 1: 82.4% Def 2: 78.8% Def 3: 80.4%	Def 1: 58.8% Def 2: 58.5% Def 3: 56%
<b>Belas 2012</b>	53.5%	Patient	22	12	23	13	64.7%	63.8%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Ibraheim 2012</b>	73.9%	Patient	14	11	57	10	56%	85.1%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Sciarra 2012</b>	34.5%	Patient	41	4	25	14	91.1%	64.1%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Portalez 2012</b>	48.1%	Lesion	Likert: 357 PI-RADS: 404	Likert: 50 PI-RADS: 47	Likert: 81 PI-RADS: 34	Likert: 50 PI-RADS: 47	Likert: 95% PI-RADS: 95%	Likert: 38% PI-RADS: 58%	maxCCL >3mm and/or GG 4/5	NR	NR	NR	NR	NR	NR	NR
<b>Watanabe 2012</b>	48.1%	Patient	485	73	624	266	86.9%	70.1%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Tamada 2011</b>	70%	Patient Region	12 277	6 48	29 55	3 20	67% 85%	91% 73%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Choi 2011</b>	70.6%	Patient	9	5	31	6	64.2%	75.7%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Iwazawa 2011</b>	40.5%	Region	887	86	232	219	91.1%	51.4%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Rouse 2011</b>	33.7%	Sextant	145	11	74	22	92.9%	77.1%	GS ≥7: Def 1 ≥3mm Def 2 ≥5mm	Def 1: 26.6% Def 2: 26.2%	Def 1: 153 Def 2: 153	Def 1: 3 Def 2: 3	Def 1: 64 Def 1: 63	Def 1: 32 Def 2: 33	Def 1: 98.1% Def 2: 98.1%	Def 1: 68.1% Def 2: 67%

										Def 1: 41.2%	Def 1: 30	Def 1: 4	Def 1: 43	Def 1: 4	Def 1: 88.2%	Def 1: 53.8%
										Def 2: 36.8%	Def 2: 31	Def 2: 3	Def 2: 39	Def 2: 3	Def 2: 91.2%	Def 2: 48.8%
	59.6%	Patient	24	14	54	22	63.2%	71.1%								
<b>Haffner 2011</b>	54.4%	Patient	154	50	240	111	75.4%	68.3%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Panebianco 2010</b>	42.7%	Patient	NR	NR	NR	NR	95.1%	88.2%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Roy 2010</b>	55.9%	Patient	NR	NR	NR	NR	71%	75%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Testa 2010</b>	40.7%	Patient	NR	NR	NR	NR	79.3%	64%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Sciarra 2010</b>	50%	Patient	61	4	66	9	93.8%	88%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Kitajima 2010</b>	56.6%	Patient	311	19	80	14	92.2%	85.1%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Labanaris 2010</b>	73.9%	Patient	17	73	96	74	81.11%	56.47%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Kumar 2009</b>	21.7%	Patient	39	3	10	8	92.8%	55%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Schmuecking 2009</b>	NR	Lobe	NR	NR	NR	NR	96%	61%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Ben Cheick 2009</b>	24.7%	Patient	36	12	11	34	80%	22.9%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Cirillo 2008</b>	31.5%	Patient	19	0	17	18	100%	48.6%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Kumar 2007</b>	13.3%	Patient	39	0	11	33	100%	25%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Squillaci 2005</b>	50.8%	Patient	29%	8%	25%	3%	89%	80%	NR	NR	NR	NR	NR	NR	NR	NR
<b>Hara 2005</b>	41.5%	Patient	≥2/3: 40 =3/3: 47	≥2/3:4 =3/3: 8	≥2/3 30 =3/3: 26	≥2/3: 8 =3/3: 1	≥2/3: 90% =3/3: 85%	≥2/3: 78.9% =3/3: 96.3%	NR	NR	NR	NR	NR	NR	NR	NR

**Table 2:** Diagnostic performance of pre-biopsy multiparametric MRI using biopsy findings as reference standard

PCa: prostate cancer; MRI: magnetic resonance imaging; TN: true negatives; FN: false negatives; FP: false positives; TP: true positives; PPV: positive predictive value; NPV: negative predictive value; vol: volume; csPCa: clinically significant prostate cancer; max: maximum; CCL: cancer core length; PSAd: PSA density; GG: Gleason grade; GS: Gleason score; SBx: systematic biopsy; TBx: targeted biopsy; NR: not reported